Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASCO GU 2014 Medivation’

This week we turn our focus to the American Society of Clinical Oncology Genitourinary (ASCO GU) symposium being held in San Francisco.

The hottest topic is highly likely to be the Medivation and Astellas data for enzalutamide (Xtandi) in the pre-chemotherapy setting in men with advanced prostate cancer who are asymptomatic or slightly symptomatic and naive to chemotherapy.  Previously, I wrote in detail about the Medivation announcement regarding the interim analysis where the PREVAIL trial was found to meet its primary endpoint (open access).

Dr Tom Beer, OHSU

Dr Tom Beer, OHSU

The company subsequently stated that the data had been accepted as a late breaker for the the ASCO Genitourinary meeting in San Francisco this weekend.  That data is being presented on Thursday morning in the oral prostate cancer session by Dr Tomasz Beer (OHSU), who is the Deputy Director of the Knight Cancer Institute and a prostate cancer specialist.

The ASCO GU 2014 abstracts will be available for perusing as of 5pm ET today.

This week I caught up with Dr Beer to discuss not only the details relating to the PREVAIL data, but also how enzalutamide (Xtandi) potentially fits in the advanced prostate cancer competitive landscape given that he also participated in the abiraterone (Zytiga) COU-AA-302 trial in the same clinical setting.

To read more about Dr Beer’s insights, you can access the article below by signing in or signing up via the box below.

This week sees the start of the American Society of Clinical Oncology Symposium on Genitourinary Cancers (ASCO GU) in San Francisco.

Prostate cancer has certainly been in the minds of investors the past few weeks in anticipation of the COMET-1 prostate cancer trial results for cabozantinib (Cometriq).

The share price went on a run-up until Exelixis CEO Michael Morrissey took yet another trip to the biotech ATM machine.  Somehow, this doesn’t come as any surprise given past performance.  The key issue at stake here, however, is will the COMET-1 trial be positive or negative?  The outcome is much anticipated and will no doubt influence the chances of successful approval for cabozantinib in advanced prostate cancer.  Data is expected sometime in first half of this year.

What we can expect in the media this week is more news on the Medivation and Astellas phase 3 trial PREVAIL clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer who had not yet received chemotherapy.  The ASCO GU abstracts are publicly available at 5pm on Tuesday.

Currently, the key data from oncology medical conferences is focused squarely on Medivation’s enzalutamide and the PREVAIL data.  It seems a good idea to discuss what are the key things to watch out for?

You can sign in or sign-up below to read the report.

error: Content is protected !!